PF-06425090の新興薬剤に関する洞察と市場予測：2032年

PfizerのPF-06425090（クロストリジウム・ディフィシルワクチン）は、50歳以上の成人における一次性CDI（P-CDI）を予防するワクチンです。二価のトキソイドワクチンで、遺伝的に無毒化された毒素であるため、重要な抗原エピトープを保持しています。2022年3月、Pfizerは、PF-06425090のCDI予防効果を評価する極めて重要な第III相CLOVER試験の結果を発表しました。同試験では、事前に規定された主要評価項目であるCDIの一次予防は達成されなかったもの、安全性評価では、治験ワクチンの安全性と忍容性が示されました。

同ワクチンは現在開発第III相にあり、Pfizerは規制当局と連携しながら、同プログラムの次のステップを評価中です。

今後数年間で、クロストリジウム・ディフィシル感染症の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、PF-06425090の優位性に影響を与える可能性のある機会を模索しています。クロストリジウム・ディフィシル感染症に対する他の新興製品がPF-06425090に厳しい市場競合を与えることが予想され、近い将来の後期新興治療薬の発売は市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるPF-06425090市場について調査し、市場の概要とともに、2025年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 クロストリジウムディフィシル感染症に対するPF-06425090の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 PF-06425090市場評価

• クロストリジウム・ディフィシル感染症に対するPF-06425090の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるクロストリジウム・ディフィシル感染症に対するPF-06425090の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: PF-06425090, Clinical Trial Description, 2023
• Table 2: PF-06425090, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: PF-06425090 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: PF-06425090 Market Size in the US, in USD million (2019-2032)
• Table 7: PF-06425090 Market Size in Germany, in USD million (2019-2032)
• Table 8: PF-06425090 Market Size in France, in USD million (2019-2032)
• Table 9: PF-06425090 Market Size in Italy, in USD million (2019-2032)
• Table 10: PF-06425090 Market Size in Spain, in USD million (2019-2032)
• Table 11: PF-06425090 Market Size in the UK, in USD million (2019-2032)
• Table 12: PF-06425090 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: PF-06425090 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: PF-06425090 Market Size in the United States, USD million (2019-2032)
• Figure 3: PF-06425090 Market Size in Germany, USD million (2019-2032)
• Figure 4: PF-06425090 Market Size in France, USD million (2019-2032)
• Figure 5: PF-06425090 Market Size in Italy, USD million (2019-2032)
• Figure 6: PF-06425090 Market Size in Spain, USD million (2019-2032)
• Figure 7: PF-06425090 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: PF-06425090 Market Size in Japan, USD million (2019-2032)

“"PF-06425090 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about PF-06425090 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the PF-06425090 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-06425090 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-06425090 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

PF-06425090 (C. difficile vaccine) by Pfizer is a vaccine to prevent primary CDI (P-CDI) in adults aged 50 and older.

A bivalent toxoid vaccine, it preserves important antigenic epitopes, as it is a genetically detoxified toxin. In March 2022, Pfizer announced results from its pivotal Phase III CLOVER trial, evaluating PF-06425090 for the prevention of CDI. Though the trial did not meet its prespecified primary endpoint of prevention of primary CDI, its safety reviews indicated that the investigational vaccine was safe and well tolerated.

The vaccine is in Phase III of development and Pfizer is currently evaluating the next steps for the program in coordination with regulatory agencies.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PF-06425090 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on PF-06425090 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PF-06425090 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PF-06425090.
• The report contains forecasted sales of PF-06425090 for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for PF-06425090 in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PF-06425090 Analytical Perspective by DelveInsight

In-depth PF-06425090 Market Assessment

This report provides a detailed market assessment of PF-06425090 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

PF-06425090 Clinical Assessment

The report provides the clinical trials information of PF-06425090 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PF-06425090 dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to PF-06425090 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PF-06425090 in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of PF-06425090 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PF-06425090 in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of PF-06425090?
• What is the clinical trial status of the study related to PF-06425090 in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PF-06425090 development?
• What are the key designations that have been granted to PF-06425090 for clostridium difficile infection?
• What is the forecasted market scenario of PF-06425090 for clostridium difficile infection?
• What are the forecasted sales of PF-06425090 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to PF-06425090 for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. PF-06425090 Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PF-06425090 Market Assessment

• 5.1. Market Outlook of PF-06425090 in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of PF-06425090 in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of PF-06425090 in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of PF-06425090 in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of PF-06425090 in France for Clostridium difficile infection
  • 5.3.4. Market Size of PF-06425090 in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of PF-06425090 in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of PF-06425090 in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of PF-06425090 in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options